Mavrilimumab, a monoclonal antibody targeting GM-CSFRα, has been shown in ex vivo cultures of GCA arteries to reduce inflammatory infiltrates, pro-inflammatory cytokines (IL-6, TNFα, IL-1β), oxidative stress, and angiogenesis [105]. This evidence concerns the gene IL1B and temporal arteritis.